First line targeted therapies in breast cancer: focus on bevacizumab.
The heterogeneity of metastatic breast cancer mandates the need to select therapies taking into account tumor and patient characteristics. Chemotherapy is indicated in the palliative setting especially when the disease is unresponsive to hormonal therapy or is hormone-receptor negative. The main chemotherapeutic agents are anthracyclines, taxanes, and capecitabine. The knowledge of the effects of currently approved agents and of the biology of breast cancer have paved the way for the evaluation of new treatment options, among which are anti-angiogenic agents. Angiogenesis inhibition has resulted in clinically significant improvements in the outcome of a variety of malignancies, including breast cancer. Bevacizumab, a monoclonal antibody anti-vascular endothelial growth factor (VEGF), is the most extensively studied anti-angiogenic compound. According to the results of a phase III trial in patients with untreated metastatic breast cancer, bevacizumab increases both objective response rate and median progression-free survival when combined with standard chemotherapy vs chemotherapy alone. The combination of anti-angiogenic drugs and other biologic agents is also being explored in an attempt to improve efficacy.
Milano
Amalia
A
Istituto Nazionale Tumori "Fondazione G. Pascale" Via M. Semmola, 80131, Napoli, Italy.
Nasti
Gugliemo
G
Iaffaioli
Rosario Vincenzo
RV
Caponigro
Francesco
F
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Cancer Res. 2001 Jul 1;61(13):5090-101
11431346
Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11
10198732
J Natl Cancer Inst. 2001 Feb 21;93(4):309-14
11181778
J Clin Invest. 1999 Oct;104(7):913-23
10510332
Endocr Rev. 1997 Feb;18(1):4-25
9034784
N Engl J Med. 1995 Dec 28;333(26):1757-63
7491141
Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
14613032
Cancer Res. 2000 Oct 15;60(20):5879-86
11059786
Hum Pathol. 1995 Jan;26(1):86-91
7821921
Nature. 1993 Apr 29;362(6423):841-4
7683111
J Clin Oncol. 2006 Feb 10;24(5):769-77
16391297
Ann Oncol. 2001 Sep;12(9):1247-54
11697835
J Biol Chem. 1997 Sep 5;272(36):22642-7
9278421
J Natl Cancer Inst. 1997 Jan 15;89(2):139-47
8998183
Cancer Res. 2001 Jul 15;61(14):5407-14
11454684
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Cancer Res. 1996 May 15;56(10):2299-301
8625303
J Clin Oncol. 2003 Feb 15;21(4):588-92
12586793
Clin Cancer Res. 2006 May 15;12(10):3124-9
16707611
J Cancer Res Clin Oncol. 1998;124(9):523-5
9808428
Mol Cell Biol. 2001 Jun;21(12):3995-4004
11359907
J Clin Oncol. 2001 Feb 1;19(3):843-50
11157038
J Am Soc Nephrol. 1998 Nov;9(11):1998-2004
9808085
Br J Cancer. 2001 May 18;84(10):1322-9
11355942
J Clin Oncol. 2005 Mar 10;23(8):1782-90
15755986
Cancer Res. 2000 Jun 1;60(11):2926-35
10850439
Cancer Res. 2004 Apr 1;64(7):2343-6
15059883
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Clin Cancer Res. 2004 Mar 1;10(5):1706-16
15014023
Eur J Cancer. 1999 Aug;35(8):1194-201
10615229
Curr Med Chem. 2006;13(16):1845-57
16842197
J Clin Oncol. 2000 Feb;18(4):724-33
10673513
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
Curr Opin Mol Ther. 2004 Jun;6(3):337-43
15264437
J Clin Oncol. 2001 Feb 1;19(3):851-6
11157039
Breast Cancer Res Treat. 2011 Dec;130(3):855-61
21874312
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
J Clin Oncol. 2005 Feb 1;23(4):792-9
15681523
J Clin Oncol. 2008 Apr 20;26(12):1993-9
18421051